Currently, the clinical development of LRRK2 kinase inhibitors is underway, highlighting their potential as a viable therapeutic option for PD.30,31 However, despite its clinical relevance, the mechanism by which increased LRRK2 kinase leads to cellular dysfunction and ultimately results in the loss of dopamine neurons remains a critical knowledge gap. The gene discussed is LRRK2; the disease is Parkinson disease.